NeoGenomics to Highlight RaDaR ST MRD Assay at ESMO Congress 2025

NeoGenomics to Report Third Quarter 2025 Financial Results on October 28, 2025

Court Rules for NeoGenomics in Patent Infringement Lawsuit Against Natera

  • NeoLINK Login
  • Investors
Search
LogoNeoLINK Login
Menu
  • Home
  • Providers
    Providers
    • Oncology solutions
      • Lung cancer
      • Breast cancer
      • Colorectal cancer
      • Gastric cancer
      • Hematologic cancers
    • Pathology solutions
      • Test search
      • Lab services
    • Client support & resources
      • Certifications & licenses
      • Test requisition forms
  • Partners
    Partners
    • Biopharma services
    • Oncology data solutions
    • Regulatory support
  • Patients
  • About NeoGenomics
    About NeoGenomics
    • Who we are
    • Scientific contributions
    • Careers
    • Privacy
    • Contact us
  • Billing
    Billing
    • For clinicians
    • For patients
    • Financial assistance
    • Pay your bill online
  • Test Search
  • Investors
Test Search
Skip to main content Skip to section navigation Skip to footer
NeoGenomics, Inc. IR Overview
  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Presentations
    • Literature
    • Email Alerts
  • Company Info
    • Overview
    • Executive Team
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Info
    • Quote
    • Chart
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • CSR
    • 2025 report
    • Inaugural Report

Press Releases

Investors News & Events Press Releases
Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Presentations
    • Literature
    • Email Alerts
  • Company Info
    • Overview
    • Executive Team
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Info
    • Quote
    • Chart
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • CSR
    • 2025 report
    • Inaugural Report
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Presentations
  • Literature
  • Email Alerts
Dec 13, 2018 7:00 am EST
NeoGenomics Appoints Dr. Lawrence M. Weiss as Chief Scientific Officer
Dec 12, 2018 7:35 am EST
NeoGenomics Announces Pricing on Secondary Offering of Common Stock by Selling Stockholder
Dec 11, 2018 4:10 pm EST
NeoGenomics Announces Secondary Offering of Common Stock by Selling Stockholder
Dec 10, 2018 9:10 am EST
NeoGenomics Completes Acquisition of Genoptix, Inc.
Nov 30, 2018 5:01 pm EST
QIAGEN and NeoGenomics collaborate to offer cancer patients Day-One access to innovative companion diagnostics for newly approved drugs
Oct 30, 2018 7:00 am EDT
NeoGenomics Reports 17% Revenue Growth to Record $69 Million
Oct 23, 2018 7:00 am EDT
NeoGenomics Signs Definitive Agreement to Acquire Genoptix
Oct 1, 2018 7:00 am EDT
NeoGenomics Schedules its Third Quarter Earnings Release for October 30, 2018
Sep 24, 2018 7:00 am EDT
NeoGenomics Announces Participation in NCI-MATCH Clinical Trial
Sep 12, 2018 8:14 am EDT
NeoGenomics Awarded Clinical Reference Laboratory Testing Services Agreement with Premier
  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 16
  • Page 17
  • Page 18
  • Page 19
  • Page 20
  • Page 21
  • Page 22
  • Page 23
  • Page 24
  • Page 25
  • …
  • Page 31
  • Next Pagearrow_forward
rss_feed News RSS
  • emailEmail Alerts
  • location_cityCompany Profile
  • rss_feedRSS News Feed
  • account_treeSitemap
©2025 NeoGenomics, Inc. All Rights Reserved.
  • Privacy Policy
  • Disclaimer
  • Sitemap
  • Accessibility Statement
  • Manage Cookie Preferences